Yellow fever - Annual Epidemiological Report for 2019
For 2019, there were no reported cases of yellow fever in the EU/EEA.
Zoonotic influenza- Annual Epidemiological Report for 2014
Annual Epidemiological Report for Zoonotic influenza, 2014
Zoonotic influenza - Annual Epidemiological Report for 2017
No human cases of avian influenza were reported in the EU/EEA. Sporadic cases were reported from Africa and Asia.
Anthrax - Annual Epidemiological Report 2016 [2014 data]
In 2014, a total of 16 cases of anthrax was reported by four EU/EEA countries. One case was reported as a confirmed case. The remaining 26 reporting countries notified zero cases.
Yellow fever - Annual Epidemiological Report for 2017
For 2017, EU/EEA countries reported one case of yellow fever. The travel-related case was reported by the Netherlands with exposure in Suriname.
Carbapenem resistant Enterobacteriaceae - second update
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.
Seasonal influenza - Annual Epidemiological Report for 2019–2020
Influenza activity started in week 45/2019 and returned to baseline levels in week 13/2020, earlier than previous seasons. Influenza viruses circulated at high levels between weeks 52/2019 and 10/2020 (based on increased proportions (40% and above) of sentinel specimens testing positive for influenza viruses). This is comparable to previous seasons.
Sequencing of SARS-CoV-2 - first update
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.